EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste
Medtronic Vascular, Inc. · Decision date Oct 16, 2026
What did the FDA decide?
The FDA record shows an OK30 decision dated 2026-10-16 for P110023/S069, filed by Medtronic Vascular, Inc. as a 30-Day Notice. The listed reason is a process change involving a manufacturer, sterilizer, packager or supplier. The supplied statement describes the scope as a sterilization monitoring change: reducing the incubation time for the biological indicator used in external process challenge devices. The product area is a superficial femoral artery stent under product code NIP.
The identifier links the notice to PMA P110023, but a supplement is not an approval of the whole stent system, and a manufacturing notice is not an original PMA. The reported purpose concerns sterilization monitoring, not new clinical evidence; the record does not show the new incubation time, the indicator or device manufacturer, validation results, or whether the FDA reviewed supporting data. The source does not establish safety or effectiveness for any clinical use.
FDA approval order statement
approval for a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P110023/S069
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular, Inc.
- Product code
- NIP
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- NIP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P110023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P110023 · Original PMA
EVERFLEX SELF-EXPANDING PERIPHERAL STENT SYSTEM (EVERFLEX)
P110023/S069 received
Application receipt date recorded by FDA.
P110023/S069 · FDA decision
30-Day Notice
P110023/S070 · Related supplement
EVERFLEX SELF-EXPANDING PERIPHERAL STENT SYSTEM (EVERFLEX)
Timeline entries are records held by MedtechLedger for P110023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA approval | Mar 7, 2012 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| Biotronik AG | PMA approval | Mar 23, 2017 | FDA | |
| Abbott Vascular (Idef Technologies Inc) | PMA approval | Mar 28, 2014 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P110023/S069
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


